The Gastroparesis Treatment Market is anticipated to reach USD 7,768.31 million by 2030 at 3.20% CAGR during the forecast period 2022-2030.Gastroparesis is a condition of delayed gastric emptying because of partial paralysis of the stomach, resulting in food remaining in the stomach for an abnormally long time. The gastric muscles contracts to move food down into the small intestine which is controlled by the vagus nerve. Damage to the vagus nerve or the muscles of the stomach and intestines causes food to move slowly resulting in Gastroparesis. Gastroparesis predominantly affects young adult females. Although Gastroparesis is frequently associated with diabetes, idiopathic Gastroparesis accounts for the greatest number of cases.
The other market driving factors of Gastroparesis are surgery on the stomach or vagus nerve, anorexia nervosa, use of narcotics that slow gastric contractions, gastroesophageal reflux disease, disorders, such as amyloidosis and scleroderma, Parkinson's disease, metabolic disorders such as hypothyroidism, etc.
Study Objectives Gastroparesis Treatment Market:
Global Gastroparesis Treatment market has been segmented on the basis of Gastroparesis type which comprises idiopathic, diabetic, post-surgical and others. On the basis of drug class the market comprises of prokinetic drugs, antiemetics, antidepressants and others. On the basis of other treatment; market is segmented into jejunostomy, gastric electric stimulation (GES) and parenteral nutrition.
Regional Analysis of Global Gastroparesis Treatment Market:
Globally America is the largest market for Gastroparesis treatment. Europe is the second-largest market for Gastroparesis Treatment. Reasons for dominance of the developed regions is the faster market uptake, higher per capita income and excellent reimbursement scenario in these regions. Asia Pacific region is expected to be witness fastest growth and most of it will be led by Japan, China and India.
The report for global Gastroparesis Treatment market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
|Market Size||USD 7,768.31 million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Gastroparesis Type, Drug Class, Other Treatment|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Medtronic, Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc., Boston Scientific Corporation, C. R. Bard, Inc., Janssen Global Services, LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, Rhythm Pharmaceuticals|
|Key Market Opportunities||
|Key Market Drivers||Rising number of cases among adult females and use of drugs for slowing gastic contractions|
Gastroparesis treatment market is expected to touch a value of USD 7,768.31 million by 2030.
Gastroparesis treatment market can showcase a CAGR of 3.20% from 2022-2030.
Gastroparesis treatment market is driven by the rising number of cases among adult females and use of drugs for slowing gastic contractions.
Lack of awareness among farmers can hamper the growth of the global gastroparesis treatment market.
Rhythm Pharmaceuticals, Inc., Janssen Global Services, Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc., LLC, Cardinal Health, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Kimberly-Clark Corporation, Medtronic, Evoke Pharma, and others are notable players of the global gastroparesis treatment market.